<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2f9d596e-65fa-2c97-e063-6394a90a29a3"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use BENZNIDAZOLE TABLETS safely and effectively. See full prescribing information for BENZNIDAZOLE TABLETS.
 <br/>
      <br/>
      <br/>
      <br/>
BENZNIDAZOLE tablets, for oral use
 <br/>
      <br/>
Initial U.S. Approval: 2017
</title>
   <effectiveTime value="20250305"/>
   <setId root="8983d6a0-f63f-4f8e-bba4-38223f39e29b"/>
   <versionNumber value="12"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="071170534"/>
            <name>Exeltis USA, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="071170534"/>
                  <name>Exeltis USA, Inc.</name>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="2f9e39af-c3b9-856f-e063-6394a90a798c"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250305"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0642-7464" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Benznidazole</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>benznidazole</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="YC42NRJ1ZD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZNIDAZOLE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YC42NRJ1ZD" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>BENZNIDAZOLE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0642-7464-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180330"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA209570" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180330"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="10" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="4" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">E</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0642-7463" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Benznidazole</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>benznidazole</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="12.5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="YC42NRJ1ZD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZNIDAZOLE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YC42NRJ1ZD" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>BENZNIDAZOLE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0642-7463-12" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180330"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA209570" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180330"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="5" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">E</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Ld35e720c-5d79-49bb-9f1f-f8e4dad1f268">
               <id root="f3f932a2-57c8-02ff-e053-2a95a90a9142"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <text/>
               <effectiveTime value="20211215"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Contraindications, Patients with Cockayne Syndrome (
    <linkHtml href="#id_link_cd0d7f54-1ba5-686d-e053-2995a90a55c6">4.3</linkHtml>, 
    <linkHtml href="#ID_9a77d6b6-46ed-4161-835d-19d40a56c75d">6.2</linkHtml>) 12/2021
   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_017948bb-fe34-4377-a6ae-26c80f694f41">
               <id root="b8b78936-ec98-898a-e053-2a95a90a7ca7"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>Benznidazole Tablets are indicated in pediatric patients 2 to 12 years of age for the treatment of Chagas disease (American trypanosomiasis) caused by 
       
 
  <content styleCode="italics">Trypanosoma cruzi</content>.  
      

 </paragraph>
                  <paragraph>This indication is approved under accelerated approval based on the number of treated patients who became Immunoglobulin G (IgG) antibody negative against the recombinant antigens of 
       
 
  <content styleCode="italics">T. cruzi [see Clinical Studies (
        
  
   <linkHtml href="#ID_36d25ff4-24ff-4b20-ad94-6b4c7d368f4d">14</linkHtml>)]
       
 
  </content>. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
      

 </paragraph>
               </text>
               <effectiveTime value="20170829"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Benznidazole Tablets, a nitroimidazole antimicrobial, is indicated in pediatric patients 2 to 12 years of age for the treatment of Chagas disease (American trypanosomiasis), caused by 
         
 
    <content styleCode="italics">Trypanosoma cruzi</content> (
         
 
    <linkHtml href="#ID_017948bb-fe34-4377-a6ae-26c80f694f41">1</linkHtml>).
        

   </paragraph>
                        <paragraph>This indication is approved under accelerated approval based on the number of treated patients who became Immunoglobulin G (IgG) antibody negative against the recombinant antigens of 
         
 
    <content styleCode="italics">T. cruzi</content>. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials (
         
 
    <linkHtml href="#ID_017948bb-fe34-4377-a6ae-26c80f694f41">1</linkHtml>, 
         
 
    <linkHtml href="#ID_36d25ff4-24ff-4b20-ad94-6b4c7d368f4d">14</linkHtml>).
        

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_a8c0ee45-70f2-4dc0-9a5c-b7273313ef2c">
               <id root="b8b78936-ec9a-898a-e053-2a95a90a7ca7"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20190531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Pediatric patients 2 to 12 years of age: The total daily dose is 5 mg/kg to 8 mg/kg orally administered in two divided doses separated by approximately 12 hours for a duration of 60 days (
          
  
     <linkHtml href="#ID_22b5ac3f-bdb3-4066-a5e8-749a5c8010bf">2.2</linkHtml>).
         
 
    </item>
                           <item>See Full Prescribing Information for important administration instructions (
          
  
     <linkHtml href="#ID_befd77e5-2f47-4dcf-bb3a-76c131c2edba">2.1</linkHtml>, 
          
  
     <linkHtml href="#ID_2280bef5-a99d-4273-a158-cbe2e329feea">2.3</linkHtml>, 
          
  
     <linkHtml href="#ID_547bb9b4-7002-4376-9427-c3f0e525ec00">2.4</linkHtml>).
         
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_befd77e5-2f47-4dcf-bb3a-76c131c2edba">
                     <id root="b8b78936-ec9b-898a-e053-2a95a90a7ca7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Administration Instructions </title>
                     <text>
                        <list listType="unordered">
                           <item>Benznidazole Tablets (12.5 mg and 100 mg) are for oral use and may be taken with or without food 
          
  
   <content styleCode="italics">[see Clinical Pharmacology (
           
   
    <linkHtml href="#ID_5ad02d1c-1e0a-449e-b0cc-fd677b08afe2">12.3</linkHtml>)]
          
  
   </content>. 
         
 
  </item>
                           <item>Benznidazole Tablets are dosed by body weight (kg) 
          
  
   <content styleCode="italics">[see Dosage and Administration (
           
   
    <linkHtml href="#ID_22b5ac3f-bdb3-4066-a5e8-749a5c8010bf">2.2</linkHtml>)]
          
  
   </content>. 
         
 
  </item>
                           <item>Benznidazole Tablets 100 mg are functionally scored tablets which can be split into one-half (50 mg) or one-quarter (25 mg) at the scored lines to provide doses less than 100 mg 
          
  
   <content styleCode="italics">[see 
           
   
    <linkHtml href="#ID_f8c9510f-0e3c-4546-bb1c-bb53d9adcf5b">Instructions for Use</linkHtml>]
          
  
   </content>. 
         
 
  </item>
                           <item>Benznidazole Tablets 12.5 mg and 100 mg can be made into slurry as an alternative method of administration 
          
  
   <content styleCode="italics">[see Dosage and Administration (
           
   
    <linkHtml href="#ID_547bb9b4-7002-4376-9427-c3f0e525ec00">2.4</linkHtml>)]
          
  
   </content>.
         
 
  </item>
                        </list>
                     </text>
                     <effectiveTime value="20170829"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_22b5ac3f-bdb3-4066-a5e8-749a5c8010bf">
                     <id root="b8b78936-ec9c-898a-e053-2a95a90a7ca7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Dosage in Pediatric Patients (2 to 12 Years of Age)  </title>
                     <text>
                        <paragraph>The total daily dose for pediatric patients 2 to 12 years of age is 5 mg/kg to 8 mg/kg orally administered in two divided doses separated by approximately 12 hours, for a duration of 60 days (see 
         
 
  <linkHtml href="#_Ref492919892">Table 1</linkHtml>).
        

 </paragraph>
                        <table ID="_Ref492919892" width="100.04%" cellpadding="3.6pt">
                           <caption>Table 1: Recommended Dosage of Benznidazole Tablets in Pediatric Patients (2 to 12 Years of Age)</caption>
                           <col width="34%"/>
                           <col width="13%"/>
                           <col width="18%"/>
                           <col width="19%"/>
                           <col width="17%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Botrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Body Weight Range (kg)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Dose (mg)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Number of Benznidazole Tablets</content>
                                       <br/>
                                       <content styleCode="bold">12.5 mg </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Number of Benznidazole Tablets </content>
                                       <br/>
                                       <content styleCode="bold">100mg </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Duration and Frequency of Therapy</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top">
                                    <paragraph>Less than 15 kg</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>50 mg</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 tablets</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>½ tablet</paragraph>
                                 </td>
                                 <td rowspan="5" align="center" valign="top">
                                    <paragraph>Administered twice daily approximately 12 hours apart for 60 days.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top">
                                    <paragraph>15 kg to less than 20 kg</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>62.5 mg</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 tablets</paragraph>
                                 </td>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td align="center" valign="top">
                                    <paragraph>20 kg to less than 30 kg</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>75 mg</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 tablets</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>¾ tablet</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top">
                                    <paragraph>30 kg to less than 40 kg</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>100 mg</paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td align="center" valign="top">
                                    <paragraph>1 tablet</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top">
                                    <paragraph>40 kg to less than 60 kg</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>150 mg</paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td align="center" valign="top">
                                    <paragraph>1 ½ tablets</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule" valign="top">
                                    <paragraph>Greater than or equal to 60 kg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule" valign="top">
                                    <paragraph>200 mg</paragraph>
                                 </td>
                                 <td styleCode="Botrule" valign="top"/>
                                 <td align="center" styleCode="Botrule" valign="top">
                                    <paragraph>2 tablets</paragraph>
                                 </td>
                                 <td styleCode="Botrule" valign="top"/>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2280bef5-a99d-4273-a158-cbe2e329feea">
                     <id root="b8b78936-ec9d-898a-e053-2a95a90a7ca7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Assessment Prior to Initiating Benznidazole Tablets </title>
                     <text>
                        <paragraph>Obtain a pregnancy test in females of reproductive potential prior to therapy with Benznidazole Tablets 
         
 
  <content styleCode="italics">[see Use is Specific Populations (
          
  
   <linkHtml href="#ID_19558b53-da39-4881-b2c7-ed61bec4dc41">8.3</linkHtml>)]
         
 
  </content>.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20190530"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_547bb9b4-7002-4376-9427-c3f0e525ec00">
                     <id root="b8b78936-ec9e-898a-e053-2a95a90a7ca7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Preparation of Slurry as an Alternative Method of Administration  </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">A. Preparation of Slurry Using Benznidazole Tablets 12.5 mg for the Pediatric Population with Body Weight Less Than 30 kg</content>
                        </paragraph>
                        <paragraph>Benznidazole Tablets 12.5 mg may be made into slurry in a specified volume of water for the pediatric population with body weight less than 30 kg (see 
         
 
  <linkHtml href="#_Ref492919908">Table 2</linkHtml>). The 12.5 mg tablet slurry is prepared by the following method:
        

 </paragraph>
                        <table ID="_Ref492919908" width="100%" cellpadding="3.6pt">
                           <caption>Table 2: Preparation and Administration of Slurry Using Benznidazole Tablets 12.5 mg for the Pediatric Population with Body Weight of Less than 30 kg</caption>
                           <col width="29%"/>
                           <col width="15%"/>
                           <col width="30%"/>
                           <col width="26%"/>
                           <tbody>
                              <tr>
                                 <td colspan="4" styleCode="Botrule Toprule" valign="top">
                                    <list listType="unordered">
                                       <item>Place the prescribed dose of Benznidazole Tablets 12.5 mg into a cup.</item>
                                       <item>Add the specified volume of water per number of 12.5 mg tablets as shown below.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Body Weight Range (kg)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Dose</content>
                                       <br/>
                                       <content styleCode="bold">(mg)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Number of Benznidazole Tablets 12.5 mg </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Quantity of Water for Preparing the Slurry</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Less than 15 kg</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>50 mg</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 tablets</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>40 mL</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>15 kg to less than 20 kg</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>62.5 mg</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 tablets</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>50 mL</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" valign="top">
                                    <paragraph>20 kg to less than 30 kg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule" valign="top">
                                    <paragraph>75 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule" valign="top">
                                    <paragraph>6 tablets</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule" valign="top">
                                    <paragraph>60 mL</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4" styleCode="Botrule" valign="top">
                                    <list listType="unordered">
                                       <item>Allow the tablets to disintegrate in the cup over a period of approximately 1-2 minutes.</item>
                                       <item>Shake the contents of the cup gently to mix.</item>
                                       <item>Drink the contents of the cup (slurry of tablets with water) immediately.</item>
                                       <item>Rinse the cup with an additional 
              
      
       <content styleCode="bold">10 mL</content> of water and drink the whole amount.
             
     
      </item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">B. Preparation of Slurry Using Benznidazole Tablets 100 mg for the Pediatric Population with Body Weight (30 kg or greater)</content>
                        </paragraph>
                        <paragraph>Benznidazole Tablets 100 mg may be made into a slurry in a specified volume of water for the pediatric population with body weight of 30 kg or greater (see 
         
 
  <linkHtml href="#_Ref492919923">Table 3</linkHtml>). The 100 mg tablet slurry is prepared as follows:
        

 </paragraph>
                        <table ID="_Ref492919923" width="100%" cellpadding="3.6pt">
                           <caption>Table 3: Preparation and Administration of Slurry Using Benznidazole Tablets 100 mg for the Pediatric Population with Body Weight 30 kg or greater</caption>
                           <col width="29%"/>
                           <col width="15%"/>
                           <col width="30%"/>
                           <col width="26%"/>
                           <tbody>
                              <tr>
                                 <td colspan="4" styleCode="Botrule Toprule" valign="top">
                                    <list listType="unordered">
                                       <item>Place the prescribed dose of Benznidazole Tablets 100 mg tablets into a cup.</item>
                                       <item>Add the specified volume of water per number of 100 mg tablets as shown below.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Body Weight Range (kg)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Dose</content>
                                       <br/>
                                       <content styleCode="bold">(mg)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Number of Benznidazole Tablets 100 mg </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Quantity of Water for Preparing the Slurry</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>30 kg to less than 40 kg</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>100 mg</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 tablet</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>80 mL</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>40 kg to less than 60 kg</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>150 mg</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 ½ tablets</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>120 mL</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" valign="top">
                                    <paragraph>Greater than or equal to 60 kg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule" valign="top">
                                    <paragraph>200 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule" valign="top">
                                    <paragraph>2 tablets</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule" valign="top">
                                    <paragraph>160 mL</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4" styleCode="Botrule" valign="top">
                                    <list listType="unordered">
                                       <item>Allow the tablet(s) to disintegrate in the cup over a period of approximately 1- 2 minutes.</item>
                                       <item>Shake the contents of the cup gently to mix.</item>
                                       <item>Drink the contents of the cup (slurry of tablet(s) with water) immediately.</item>
                                       <item>Rinse the cup by adding 
              
      
       <content styleCode="bold">80 mL</content> of water and drink the whole amount. Repeat this rinse with 
              
      
       <content styleCode="bold">80 mL</content> of water and drink again.
             
     
      </item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_c490d7b0-7acc-463a-8f02-cd0f1f2461fb">
               <id root="b8b78936-ec9f-898a-e053-2a95a90a7ca7"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Benznidazole Tablets are available as 100 mg and 12.5 mg tablets. </paragraph>
                  <paragraph>The 100 mg white tablets are round and functionally scored twice as a cross on both sides, debossed with “E” on one side of each quarter portion. </paragraph>
                  <paragraph>The 12.5 mg white tablets are round and unscored, debossed with “E” on one side.</paragraph>
               </text>
               <effectiveTime value="20191112"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Tablets: 100 mg (functionally scored) (
          
  
     <linkHtml href="#ID_c490d7b0-7acc-463a-8f02-cd0f1f2461fb">3</linkHtml>).
         
 
    </item>
                           <item>Tablets: 12.5 mg (
          
  
     <linkHtml href="#ID_c490d7b0-7acc-463a-8f02-cd0f1f2461fb">3</linkHtml>).
         
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_dfd0cac7-eae1-409e-bd9b-49dbf3ce7a66">
               <id root="cec4ec3d-4b44-f499-e053-2995a90a8c28"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <effectiveTime value="20210930"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>• History of hypersensitivity reaction to benznidazole or other nitroimidazole derivatives ( 
    <linkHtml href="#ID_16c97f21-c63c-493d-9048-6b94ac5dcea0">4.1</linkHtml>).
   </paragraph>
                        <paragraph>• Disulfiram usage within the last two weeks ( 
    <linkHtml href="#ID_d17b43de-9522-4207-8b30-ddeb5a791dec">4.2</linkHtml>).
   </paragraph>
                        <paragraph>• Patients with Cockayne Syndrome (
    <linkHtml href="#id_link_cd0d7f54-1ba5-686d-e053-2995a90a55c6">4.3</linkHtml>, 
    <linkHtml href="#ID_9a77d6b6-46ed-4161-835d-19d40a56c75d">6.2</linkHtml>).
   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_16c97f21-c63c-493d-9048-6b94ac5dcea0">
                     <id root="b8b78936-eca1-898a-e053-2a95a90a7ca7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.1 Hypersensitivity </title>
                     <text>
                        <paragraph>Benznidazole Tablets are contraindicated in patients with a history of hypersensitivity reaction to benznidazole or other nitroimidazole derivatives. Reactions have included severe skin and soft tissue reactions 
         
 
  <content styleCode="italics">[see Adverse Reactions (
          
  
   <linkHtml href="#ID_fec6e961-8cc3-4e30-961c-9f6e4bd7c55a">6.1</linkHtml>)]
         
 
  </content>.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20170829"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d17b43de-9522-4207-8b30-ddeb5a791dec">
                     <id root="b8b78936-eca2-898a-e053-2a95a90a7ca7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.2 Disulfiram </title>
                     <text>
                        <paragraph>Benznidazole Tablets are contraindicated in patients who have taken disulfiram within the last two weeks.  Psychotic reactions may occur in patients who are using benznidazole and disulfiram concurrently 
         
 
  <content styleCode="italics">[see Drug Interactions (
          
  
   <linkHtml href="#ID_73bdb390-3c5e-4972-bf62-b1f203157e7f">7.1</linkHtml>)]
         
 
  </content>.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20170829"/>
                  </section>
               </component>
               <component>
                  <section ID="id_link_cd0d7f54-1ba5-686d-e053-2995a90a55c6">
                     <id root="cec4ec3d-4b43-f499-e053-2995a90a8c28"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.3 Patients with Cockayne Syndrome</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Benznidazole Tablets are contraindicated in patients with Cockayne syndrome. Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole, another nitroimidazole drug, structurally related to benznidazole in patients with Cockayne syndrome 
   <content styleCode="italics">[see Adverse Reactions (
    <linkHtml href="#ID_9a77d6b6-46ed-4161-835d-19d40a56c75d">6.2</linkHtml>)]
   </content>.
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20210930"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_7f01d443-be54-485a-80fc-a717720bb9ba">
               <id root="f489ce39-49a8-2a9c-e053-2a95a90a8886"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20211215"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Potential Risk for Genotoxicity and Carcinogenicity ( 
     <linkHtml href="#ID_59164ae1-e3b0-4daa-92a5-8ac5a2211866">5.1</linkHtml>).
    </item>
                           <item>Embryo-Fetal Toxicity: Can cause fetal harm. Pregnancy testing is recommended for females of reproductive potential. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception ( 
     <linkHtml href="#ID_2280bef5-a99d-4273-a158-cbe2e329feea">2.3</linkHtml>, 
     <linkHtml href="#ID_8e159c11-bef9-4e18-8869-8636261b77c0">5.2</linkHtml>, 
     <linkHtml href="#ID_e5a4b606-4d6b-4c5b-b890-622e152979b6">8.1</linkHtml>, 
     <linkHtml href="#ID_19558b53-da39-4881-b2c7-ed61bec4dc41">8.3</linkHtml>).
    </item>
                           <item>Hypersensitivity skin reactions have been reported with benznidazole. In case of skin reactions, presenting with additional symptoms of systemic involvement such as lymphadenopathy, fever and/or purpura, discontinuation of treatment is recommended ( 
     <linkHtml href="#ID_d1bc0bba-d8ff-4023-a0c9-2aad1926083d">5.3</linkHtml>).
    </item>
                           <item>Treatment with Benznidazole Tablets can potentially cause paresthesia or symptoms of peripheral neuropathy. In cases where neurological symptoms occur, immediate discontinuation of treatment is recommended ( 
     <linkHtml href="#ID_ba2c26c9-eb44-4535-893b-9ed3eb54c45c">5.4</linkHtml>).
    </item>
                           <item>There have been hematological manifestations of bone marrow depression, such as neutropenia, thrombocytopenia, anemia, and leukopenia ( 
     <linkHtml href="#ID_e6616b3d-2c91-4822-96f1-be2ec29d3cc9">5.5</linkHtml>).
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_59164ae1-e3b0-4daa-92a5-8ac5a2211866">
                     <id root="f4899d86-e138-2e66-e053-2a95a90a9938"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Potential for Genotoxicity and Carcinogenicity</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Genotoxicity </content>
                        </paragraph>
                        <paragraph>Genotoxicity of benznidazole has been demonstrated in humans, in vitro in several bacterial species and mammalian cell systems, and in vivo in rodents 
  <content styleCode="italics">[see Nonclinical Toxicology ( 
   <linkHtml href="#ID_7ca764cb-6802-43b0-9ba0-4930fc1aa431">13.1</linkHtml>)] 
  </content>.
 </paragraph>
                        <paragraph>A study evaluating the cytogenetic effect of benznidazole in pediatric patients ranging from 11 months to 11 years of age (the safety and effectiveness of Benznidazole Tablets in patients less than 2 years old has not been established) with Chagas disease demonstrated a two-fold increase in chromosomal aberrations. In pediatric patients with Chagas disease who were treated with benznidazole, the median incidence of micronucleated interphase lymphocytes in 20 patients increased 2-fold compared to pre-dose values. In the same study, the mean incidence of chromosomal aberrations in 10 patients also increased 2-fold compared to pre-dose values.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Carcinogenicity</content>
                        </paragraph>
                        <paragraph>Carcinogenicity has been observed in mice and rats treated chronically with nitroimidazole agents which are structurally similar to benznidazole. Similar data have not been reported for benznidazole 
  <content styleCode="italics">[see Nonclinical Toxicology ( 
   <linkHtml href="#ID_7ca764cb-6802-43b0-9ba0-4930fc1aa431">13.1</linkHtml>)] 
  </content>. It is not known whether benznidazole is associated with carcinogenicity in humans.
 </paragraph>
                     </text>
                     <effectiveTime value="20170829"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_8e159c11-bef9-4e18-8869-8636261b77c0">
                     <id root="b8b78936-eca5-898a-e053-2a95a90a7ca7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Embryo-Fetal Toxicity </title>
                     <text>
                        <paragraph>Based on findings from animal studies, Benznidazole Tablets can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, benznidazole administered orally to pregnant rats and rabbits during organogenesis was associated with fetal malformations at doses approximately 1-3 times the maximum recommended human dose (MRHD) in rats (anasarca, anophthalmia, and/or microphthalmia) and doses approximately 0.3-1 times the MRHD in rabbits (ventricular septal defect).  In rats, reduced maternal weights and smaller litter sizes occurred at a dose approximately 3 times the MRHD. In rabbits, reduced maternal weight gain, and abortions in 2/20 females occurred at a dose approximately equal to the MHRD 
         
 
  <content styleCode="italics">[see Use in Specific Populations (
          
  
   <linkHtml href="#ID_e5a4b606-4d6b-4c5b-b890-622e152979b6">8.1</linkHtml>)]
         
 
  </content>. Advise pregnant women of the potential risk to a fetus. Pregnancy testing is recommended for females of reproductive potential 
         
 
  <content styleCode="italics">[see Dosage and Administration (
          
  
   <linkHtml href="#ID_2280bef5-a99d-4273-a158-cbe2e329feea">2.3</linkHtml>)]
         
 
  </content>.  Advise females of reproductive potential to use effective contraception during treatment with Benznidazole Tablets and for 5 days after the last dose 
         
 
  <content styleCode="italics">[see Use in Specific Populations (
          
  
   <linkHtml href="#ID_e5a4b606-4d6b-4c5b-b890-622e152979b6">8.1</linkHtml>, 
          
  
   <linkHtml href="#ID_19558b53-da39-4881-b2c7-ed61bec4dc41">8.3</linkHtml>) and Clinical Pharmacology (
          
  
   <linkHtml href="#ID_5ad02d1c-1e0a-449e-b0cc-fd677b08afe2">12.3</linkHtml>)]
         
 
  </content>.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20170829"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d1bc0bba-d8ff-4023-a0c9-2aad1926083d">
                     <id root="b8b78936-eca6-898a-e053-2a95a90a7ca7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Hypersensitivity Skin Reactions </title>
                     <text>
                        <paragraph>Serious skin and subcutaneous disorders including acute generalized exanthematous pustulosis (AGEP), toxic epidermal necrolysis (TEN), erythema multiforme, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported with benznidazole. Discontinue treatment at the first evidence of these serious cutaneous reactions 
         
 
  <content styleCode="italics">[see Adverse Reactions (
          
  
   <linkHtml href="#ID_9a77d6b6-46ed-4161-835d-19d40a56c75d">6.2</linkHtml>)]
         
 
  </content>.
        

 </paragraph>
                        <paragraph>Extensive skin reactions, such as rash (maculopapular, pruritic macules, eczema, pustules, erythematous, generalized, and allergic dermatitis, exfoliative dermatitis) have also been reported. Most cases occurred after approximately 10 days of treatment with benznidazole. Most rashes resolved with treatment discontinuation.</paragraph>
                        <paragraph>In case of skin reactions presenting with additional symptoms or signs of systemic involvement such as lymphadenopathy, fever and/or purpura, discontinuation of treatment is recommended.</paragraph>
                     </text>
                     <effectiveTime value="20190530"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ba2c26c9-eb44-4535-893b-9ed3eb54c45c">
                     <id root="b8b78936-eca7-898a-e053-2a95a90a7ca7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Central and Peripheral Nervous System Effects </title>
                     <text>
                        <paragraph>Treatment with Benznidazole Tablets can cause paresthesia or symptoms of peripheral neuropathy that may take several months to resolve.  Headache and dizziness have been reported. In cases where neurological symptoms occur, immediate discontinuation of treatment is recommended. In most cases, symptoms occur late in the course of treatment.</paragraph>
                     </text>
                     <effectiveTime value="20170829"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e6616b3d-2c91-4822-96f1-be2ec29d3cc9">
                     <id root="b8b78936-eca8-898a-e053-2a95a90a7ca7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Hematological Manifestations of Bone Marrow Depression </title>
                     <text>
                        <paragraph>There have been reports of hematological manifestations of bone marrow depression, such as neutropenia, thrombocytopenia, anemia and leukopenia, which resolved after treatment discontinuation 
         
 
  <content styleCode="italics">[see Adverse Reactions (
          
  
   <linkHtml href="#ID_fec6e961-8cc3-4e30-961c-9f6e4bd7c55a">6.1</linkHtml>)]
         
 
  </content>. Patients with hematological manifestations of bone marrow depression must take Benznidazole Tablets only under strict medical supervision. Monitor complete blood count. Total and differential leukocyte counts are recommended before, during and after therapy.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20170829"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3ccf856b-941d-4429-930e-ef22bd39226f">
               <id root="cd0dc7a9-602d-67ce-e053-2995a90afd00"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious and otherwise important adverse reactions are discussed in greater detail in other sections of labeling:</paragraph>
                  <list listType="unordered">
                     <item>Potential for Genotoxicity, Carcinogenicity, and Mutagenicity 
   <content styleCode="italics">[see Warnings and Precautions ( 
    <linkHtml href="#ID_59164ae1-e3b0-4daa-92a5-8ac5a2211866">5.1</linkHtml>)] 
   </content>
                     </item>
                     <item>Hypersensitivity Skin Reactions 
   <content styleCode="italics">[see Warnings and Precautions ( 
    <linkHtml href="#ID_d1bc0bba-d8ff-4023-a0c9-2aad1926083d">5.3</linkHtml>)] 
   </content>
                     </item>
                     <item>Central and Peripheral Nervous System Effects 
   <content styleCode="italics">[see Warnings and Precautions ( 
    <linkHtml href="#ID_ba2c26c9-eb44-4535-893b-9ed3eb54c45c">5.4</linkHtml>)] 
   </content>
                     </item>
                     <item>Hematological Manifestations of Bone Marrow Depression 
   <content styleCode="italics">[see Warnings and Precautions ( 
    <linkHtml href="#ID_e6616b3d-2c91-4822-96f1-be2ec29d3cc9">5.5</linkHtml>)] 
   </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20210930"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions observed were abdominal pain, rash, decreased weight, headache, nausea, vomiting, neutropenia, urticaria, pruritus, eosinophilia, decreased appetite ( 
    <linkHtml href="#ID_fec6e961-8cc3-4e30-961c-9f6e4bd7c55a">6.1</linkHtml>).
    <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Exeltis USA, Inc. at 1-877-324-9349 or FDA at 1-800-FDA-1088 or 
     <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_fec6e961-8cc3-4e30-961c-9f6e4bd7c55a">
                     <id root="b8b78936-ecaa-898a-e053-2a95a90a7ca7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trial Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>Benznidazole was evaluated in two randomized, double-blind, placebo-controlled trials (Trial 1
         
 
  <sup>1</sup> and Trial 2
         
 
  <sup>2</sup>) and one uncontrolled trial (Trial 3
         
 
  <sup>3</sup>).
        

 </paragraph>
                        <paragraph>Trial 1 was conducted in pediatric patients 6 to 12 years of age with chronic indeterminate Chagas disease in Argentina. The chronic indeterminate form includes patients with serologic evidence of 
         
 
  <content styleCode="italics">T. cruzi</content> infection without symptoms of cardiac or gastrointestinal disease. A total of 106 patients were randomized to receive either benznidazole (5 mg/kg/day twice daily for 60 days; N= 55) or placebo (N=51) and followed for 4 years.
        

 </paragraph>
                        <paragraph>Trial 2 was conducted in pediatric patients 7 to 12 years of age with chronic indeterminate Chagas disease in Brazil. A total of 129 patients were randomized to receive either benznidazole (7.5 mg/kg/day twice daily for 60 days; N = 64) or placebo (N = 65) and followed for 3 years.</paragraph>
                        <paragraph>Trial 3 was an uncontrolled study in pediatric patients 2 to 12 years of age with chronic indeterminate Chagas disease. A total of 37 pediatric patients with Chagas disease were enrolled in this safety and pharmacokinetics study. Patients were treated with benznidazole 5 to 8 mg/kg/day twice daily for 60 days.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Adverse Reactions Leading to Discontinuation </content>
                        </paragraph>
                        <paragraph>In Trial 1, benznidazole was discontinued due to an adverse reaction in 5/55 (9%) patients. Some patients had more than one adverse reaction resulting in treatment discontinuation. The adverse reactions included abdominal pain, nausea, vomiting, rash, decreased appetite, headache, and transaminases increased.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Common Adverse Reactions in Pediatric Patients</content>
                        </paragraph>
                        <paragraph>The most frequently reported adverse reactions in pediatric patients treated with benznidazole in Trial 1 were abdominal pain (25%), rash (16%), decreased weight (13%), and headache (7%). 
         
 
  <linkHtml href="#_Ref492920038">Table 4</linkHtml> lists adverse reactions occurring at a rate of 1% or greater in pediatric patients with Chagas disease aged 6 to 12 years of age in Trial 1.
        

 </paragraph>
                        <table ID="_Ref492920038" width="100%" cellpadding="3.6pt">
                           <caption>Table 4: Adverse Reactions Occurring in Pediatric Patients with Chagas Disease aged 6 to 12 Years in Trial 1</caption>
                           <col width="31%"/>
                           <col width="26%"/>
                           <col width="21%"/>
                           <col width="23%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Body System</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Benznidazole </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=55)</content>
                                       <br/>
                                       <content styleCode="bold">N (%)</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Placebo </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=51)</content>
                                       <br/>
                                       <content styleCode="bold">N (%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Gastrointestinal</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>Abdominal pain</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>14 (25)</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>4 (8)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top"/>
                                 <td valign="top">
                                    <paragraph>Weight decreased</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>7 (13)</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top"/>
                                 <td valign="top">
                                    <paragraph>Nausea</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>3 (5)</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top"/>
                                 <td valign="top">
                                    <paragraph>Vomiting</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>3 (5)</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top"/>
                                 <td valign="top">
                                    <paragraph>Diarrhea</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>2 (4)</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" valign="top"/>
                                 <td styleCode="Botrule" valign="top">
                                    <paragraph>Decreased appetite</paragraph>
                                 </td>
                                 <td styleCode="Botrule" valign="top">
                                    <paragraph>3 (5)</paragraph>
                                 </td>
                                 <td styleCode="Botrule" valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" valign="top">
                                    <paragraph>Skin and subcutaneous tissue</paragraph>
                                 </td>
                                 <td styleCode="Botrule" valign="top">
                                    <paragraph>Rash</paragraph>
                                 </td>
                                 <td styleCode="Botrule" valign="top">
                                    <paragraph>9 (16)</paragraph>
                                 </td>
                                 <td styleCode="Botrule" valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" valign="top">
                                    <paragraph>Metabolism/Laboratory</paragraph>
                                 </td>
                                 <td styleCode="Botrule" valign="top">
                                    <paragraph>Transaminases increased</paragraph>
                                 </td>
                                 <td styleCode="Botrule" valign="top">
                                    <paragraph>3 (5)</paragraph>
                                 </td>
                                 <td styleCode="Botrule" valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Nervous system Disorders</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>Dizziness</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>2 (4)</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>2 (4)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top"/>
                                 <td valign="top">
                                    <paragraph>Peripheral neuropathy</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" valign="top"/>
                                 <td styleCode="Botrule" valign="top">
                                    <paragraph>Tremor</paragraph>
                                 </td>
                                 <td styleCode="Botrule" valign="top">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                                 <td styleCode="Botrule" valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In Trial 2, skin lesions were reported in 7 of 64 (11%) pediatric patients treated with benznidazole and in 2 of 65 patients receiving placebo. Adverse reactions reported in fewer than 5% of benznidazole-treated patients included nausea, anorexia, headache, abdominal pain and arthralgia.</paragraph>
                        <paragraph>In a subset of 19 pediatric patients 2 to 6 years of age treated with benznidazole in Trial 3, 6 patients (32%) had the following adverse reactions: rash, leukopenia, urticaria, eosinophilia, decreased appetite, and neutropenia. These adverse reactions were similar to those observed in the overall population of 37 patients.</paragraph>
                     </text>
                     <effectiveTime value="20191112"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9a77d6b6-46ed-4161-835d-19d40a56c75d">
                     <id root="cd0dc7a9-602c-67ce-e053-2995a90afd00"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during the use of other formulations of benznidazole outside of the United States, or other nitroimidazole agents . Because these reactions are reported from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph/>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="xmChange">Other Formulations of Benznidazole:</content>
                        </paragraph>
                        <table cellpadding="3.6pt" width="100%" ID="_RefID0EABAG">
                           <caption>Table 5: Adverse Reactions Reported in the Published Literature</caption>
                           <colgroup>
                              <col width="33%"/>
                              <col width="67%"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Body System</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reactions</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Rrule" valign="top">
                                    <paragraph>Dermatological</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule" valign="top">
                                    <list listType="unordered">
                                       <item>Maculo-papular cutaneous eruptions</item>
                                       <item>Erythematous plaques</item>
                                       <item>Rash, generalized</item>
                                       <item>Rash, erythematous</item>
                                       <item>Pruritic rash</item>
                                       <item>Blistering eruptions</item>
                                       <item>Peeling skin</item>
                                       <item>Exfoliative dermatitis</item>
                                       <item>Toxic epidermal necrolysis</item>
                                       <item>AGEP</item>
                                       <item>Erythema multiforme</item>
                                       <item>Drug reaction with eosinophilia and systemic symptoms (DRESS)</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Rrule" valign="top">
                                    <paragraph>Neurological (central and peripheral nervous system)</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule" valign="top">
                                    <list listType="unordered">
                                       <item>Paresthesia</item>
                                       <item>Hypoesthesia</item>
                                       <item>Headaches</item>
                                       <item>Insomnia</item>
                                       <item>Convulsions</item>
                                       <item>Inability to concentrate</item>
                                       <item>Amnesia, temporary</item>
                                       <item>Disorientation, temporary</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Rrule" valign="top">
                                    <paragraph>Gastrointestinal</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule" valign="top">
                                    <list listType="unordered">
                                       <item>Epigastric pain</item>
                                       <item>Dry mouth</item>
                                       <item>Ageusia</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Rrule" valign="top">
                                    <paragraph>Hepatobiliary disorders</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule" valign="top">
                                    <list listType="unordered">
                                       <item>Hepatitis</item>
                                       <item>Toxic hepatitis</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Rrule" valign="top">
                                    <paragraph>Skeletal Muscle</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule" valign="top">
                                    <list listType="unordered">
                                       <item>Myalgia</item>
                                       <item>Musculoskeletal pain</item>
                                       <item>Migratory arthritis</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Rrule" valign="top">
                                    <paragraph>General / Constitutional Symptoms</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule" valign="top">
                                    <list listType="unordered">
                                       <item>Fever</item>
                                       <item>Asthenia</item>
                                       <item>Fatigue</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Rrule" valign="top">
                                    <paragraph>Lymphatic</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule" valign="top">
                                    <list listType="unordered">
                                       <item>Generalized edema</item>
                                       <item>Eyelid edema</item>
                                       <item>Edema in the extremities</item>
                                       <item>Lymphadenopathy</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Rrule" valign="top">
                                    <paragraph>Bone Marrow</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule" valign="top">
                                    <list listType="unordered">
                                       <item>Thrombocytopenia</item>
                                       <item>Granulocytopenia</item>
                                       <item>Agranulocytosis</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Rrule" valign="top">
                                    <paragraph>Metabolism / Laboratory</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule" valign="top">
                                    <list listType="unordered">
                                       <item>Elevation of alkaline phosphatase</item>
                                       <item>Elevation of bilirubin</item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="xmChange"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="underline">Metronidazole, Another Nitroimidazole Agent, Structurally Related to Benznidazole </content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Cases of severe irreversible hepatotoxicity/acute liver failure, including cases with fatal outcomes with very rapid onset after initiation of systemic use of metronidazole, another nitroimidazole agent structurally related to benznidazole, have been reported in patients with Cockayne syndrome (latency from drug start to signs of liver failure as short as 2 days) 
   <content styleCode="italics">[see Contraindications (
    <linkHtml href="#id_link_cd0d7f54-1ba5-686d-e053-2995a90a55c6">4.3</linkHtml>)]
   </content>.
  </content>
                        </paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20210930"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_596e9297-dc2f-4e5c-9e5b-684c601bdf89">
               <id root="b8b78936-ecac-898a-e053-2a95a90a7ca7"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <effectiveTime value="20191112"/>
               <component>
                  <section ID="ID_73bdb390-3c5e-4972-bf62-b1f203157e7f">
                     <id root="b8b78936-ecad-898a-e053-2a95a90a7ca7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Disulfiram </title>
                     <text>
                        <paragraph>Psychotic reactions have been reported in patients who are concurrently taking disulfiram and nitroimidazole agents (structurally related to benznidazole, but not with benznidazole). Benznidazole Tablets should not be given to patients who have taken disulfiram within the last two weeks 
         
 
  <content styleCode="italics">[see Contraindications (
          
  
   <linkHtml href="#ID_d17b43de-9522-4207-8b30-ddeb5a791dec">4.2</linkHtml>)]
         
 
  </content>.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20170829"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_90144484-f177-4449-bbb9-f947caf062e7">
                     <id root="b8b78936-ecae-898a-e053-2a95a90a7ca7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Alcohol and Products Containing Propylene Glycol </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">In</content>
                           <content styleCode="italics"> vitro</content> studies showed that benznidazole, at concentrations from 0.03 μM to 100 μM, does not inhibit the enzymatic activity of human alcohol dehydrogenase (ALDH). Benznidazole Tablets are not expected to cause alcohol aversion or a disulfiram-like reaction as a result of ethanol ingestion.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20191112"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_68605966-94a7-4cb4-84e4-a2981ff6557c">
               <id root="f489ce39-49a7-2a9c-e053-2a95a90a8886"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20211215"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Lactation: Breastfeeding is not recommended ( 
    <linkHtml href="#ID_5f6aae0e-5346-4c53-ba9d-906fce645706">8.2</linkHtml>).
    <br/>
                           <br/>
                           <br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_e5a4b606-4d6b-4c5b-b890-622e152979b6">
                     <id root="f489e0d0-0eec-692f-e053-2a95a90ac191"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20191215"/>
                     <component>
                        <section ID="ID_611a7ade-0607-4fb4-ac84-c2c24241956e">
                           <id root="f489b4b7-1be5-96b3-e053-2a95a90ad140"/>
                           <code code="69759-9" codeSystem="2.16.840.1.113883.6.1" displayName="RISKS"/>
                           <title>
                              <content styleCode="underline">Risk Summary</content>
                           </title>
                           <text>
                              <paragraph>Based on findings from animal studies, Benznidazole Tablets may cause fetal harm when administered to a pregnant woman. Published postmarketing reports on benznidazole use during pregnancy are insufficient to inform a drug-associated risk of adverse pregnancy-related outcomes. There are risks to the fetus associated with Chagas Disease 
  <content styleCode="italics">(see 
   <linkHtml href="#ID_a6cff758-3972-419c-b7df-b5930d555db6">Clinical Considerations</linkHtml>) 
  </content>. In embryo-fetal development studies, benznidazole administered orally to pregnant rats and rabbits during organogenesis was associated with fetal malformations at doses approximately 1-3 times the MRHD in rats (anasarca, anophthalmia, and/or microphthalmia) and doses approximately 0.3-1.0 times the MRHD in rabbits (ventricular septal defect). In pregnant rats administered benznidazole during gestation and through lactation, effects in first generation offspring included reduced fertility in individual males and reduced numbers of live embryos and fetuses in pregnant females at a maternal dose equivalent to approximately 1.5 times the MRHD 
  <content styleCode="italics">(see 
   <linkHtml href="#ID_b6ec635e-5462-4a54-8bf5-36efb6a4f4b8">Data</linkHtml>) 
  </content>. Advise pregnant women of the potential risk to a fetus.
 </paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20191113"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_a6cff758-3972-419c-b7df-b5930d555db6">
                           <id root="b8b78936-ecb2-898a-e053-2a95a90a7ca7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Clinical Considerations</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Disease-associated Maternal and/or Embryo/Fetal Risk</content>
                              </paragraph>
                              <paragraph>Published data from case-control and observational studies on chronic Chagas disease during pregnancy are inconsistent in their findings. Some studies showed an increased risk of pregnancy loss, prematurity and neonatal mortality in pregnant women who have chronic Chagas disease while other studies did not demonstrate these findings. Chronic Chagas disease is usually not life-threatening. Since pregnancy findings are inconsistent, treatment of chronic Chagas disease during pregnancy is not recommended due to risk of embryo-fetal toxicity from Benznidazole Tablets.</paragraph>
                              <paragraph>Acute symptomatic Chagas disease is rare in pregnant women; however, symptoms may be serious or life-threatening. There have been reports of pregnant women with life-threatening symptoms associated with acute Chagas disease who were treated with benznidazole. If a pregnant woman presents with acute symptomatic Chagas disease, the risks versus benefits of treatment with Benznidazole Tablets to the mother and the fetus should be evaluated on a case-by-case basis.</paragraph>
                           </text>
                           <effectiveTime value="20191113"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_b6ec635e-5462-4a54-8bf5-36efb6a4f4b8">
                           <id root="f489b4b7-1be6-96b3-e053-2a95a90ad140"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Data</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Animal Data</content>
                              </paragraph>
                              <paragraph>In an embryo-fetal toxicity study in pregnant rats, benznidazole was administered in oral doses of 15, 50, and 150 mg/kg/day during organogenesis (days 6-17 of gestation), and the high dose was associated with maternal weight loss, reduced fetal weights, and smaller litter sizes. Benznidazole was also associated with a low incidence of fetal malformations including anasarca in one fetus at a dose of 50 mg/kg/day and anasarca and eye abnormalities (anophthalmia and microphthalmia) in 5 fetuses in 5 litters at a high dose of 150 mg/kg/day (approximately equivalent to 1 and 3 times, respectively, the MRHD based on whole body surface area comparisons). No maternal toxicity was observed at a benznidazole dose of 50 mg/kg/day (approximately equal to the MRHD based on body surface area comparison), and no fetal toxicity was observed at a dose of 15 mg/kg/day (approximately equivalent to 0.3 times the MRHD based on whole body surface area comparison).</paragraph>
                              <paragraph>In an embryo-fetal study in pregnant rabbits benznidazole administered by oral (gavage) in doses of 2.5, 7.5, and 25 mg/kg/day during organogenesis (days 6 to 19 of gestation) was associated with maternal toxicity at the high dose, including reduced weight gain and food consumption and abortions in 2/20 females. Benznidazole was also associated with a low incidence of fetal abnormalities including ventricular septal defect in 2 fetuses in 2 litters at a dose of 7.5 mg/kg/day and in 1 fetus at a dose of 25 mg/kg/day (approximately equivalent to 0.3 and 1 times respectively the MRHD based on whole body surface area comparison).The benznidazole doses that were not associated with maternal and fetal toxicity in this study were 7.5 and 2.5 mg/kg/day respectively, which are respectively equivalent to approximately 0.3 and 0.1 times the MRHD based on whole body surface area comparison.</paragraph>
                              <paragraph>In a pre-postnatal study in rats, first generation (F 
  <sub>1</sub>) pups born to dams administered 15, 50, and 75 mg/kg/day benznidazole from day 6 of gestation to day 20 of lactation demonstrated normal pre-weaning behavior, physical and functional development, neurological findings, and reproductive parameters. However, cesarean section data for the pregnant first generation (F 
  <sub>1</sub>) females in the high-dose group included significantly higher pre-implantation loss and significantly lower mean values for corpora lutea counts, number of implantations, and number of live embryos. Also, small testes and/or epididymides were observed in 1/20 and 2/20 first generation males in the mid- and high-dose groups respectively, and two of the affected animals failed to mate or induce pregnancy. However, the mean values for mating performance, fertility index, testes weight, testes and epididymides sperm counts, and epididymal sperm motility and progression were not altered in any of the F 
  <sub>1</sub> males in benznidazole treatment groups. The number of live second generation (F 
  <sub>2</sub>) fetuses born to F 
  <sub>1</sub> dams was reduced in the high-dose group. The benznidazole dose that was not associated with adverse effects was considered to be 50 mg/kg/day which is approximately equal to the MRHD based on whole body surface area comparison.
 </paragraph>
                           </text>
                           <effectiveTime value="20191112"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_5f6aae0e-5346-4c53-ba9d-906fce645706">
                     <id root="b8b78936-ecb4-898a-e053-2a95a90a7ca7"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <effectiveTime value="20170829"/>
                     <component>
                        <section ID="ID_580189ef-1cb5-482d-a267-98625434221b">
                           <id root="b8b78936-ecb5-898a-e053-2a95a90a7ca7"/>
                           <code code="69759-9" codeSystem="2.16.840.1.113883.6.1" displayName="RISKS"/>
                           <title>
                              <content styleCode="underline">Risk Summary</content>
                           </title>
                           <text>
                              <paragraph>Limited published literature based on breast milk sampling reports that benznidazole is present in human milk at infant doses of 5.5 to 17% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 0.3-2.79.  There are no reports of adverse effects on the breastfed infant and no information on the effects of benznidazole on milk production. Because of the potential for serious adverse reactions, and transmission of Chagas disease, advise patients that breastfeeding is not recommended during treatment with Benznidazole Tablets.</paragraph>
                           </text>
                           <effectiveTime value="20170829"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_19558b53-da39-4881-b2c7-ed61bec4dc41">
                     <id root="b8b78936-ecb6-898a-e053-2a95a90a7ca7"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential </title>
                     <effectiveTime value="20191112"/>
                     <component>
                        <section ID="ID_b0848441-d45d-4c67-be6c-e2366b58ee54">
                           <id root="b8b78936-ecb7-898a-e053-2a95a90a7ca7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Pregnancy Testing</content>
                           </title>
                           <text>
                              <paragraph>Pregnancy testing is recommended for females of reproductive potential.</paragraph>
                           </text>
                           <effectiveTime value="20170829"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_412388f4-c7d0-48cc-92e5-41646e834265">
                           <id root="b8b78936-ecb8-898a-e053-2a95a90a7ca7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Contraception</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Females</content>
                              </paragraph>
                              <paragraph>Benznidazole Tablets can cause fetal harm when administered to a pregnant woman 
           
 
  <content styleCode="italics">[see Use in Specific Populations (
            
  
   <linkHtml href="#ID_e5a4b606-4d6b-4c5b-b890-622e152979b6">8.1</linkHtml>)]
           
 
  </content>. Advise females of reproductive potential to use effective contraception during treatment with Benznidazole Tablets and for 5 days after the final dose.
          

 </paragraph>
                           </text>
                           <effectiveTime value="20170829"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_450a2767-736a-494b-aea3-e6bf401699d3">
                           <id root="b8b78936-ecb9-898a-e053-2a95a90a7ca7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Infertility</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Males</content>
                              </paragraph>
                              <paragraph>Based on findings in rats, Benznidazole Tablets may impair fertility in males of reproductive potential. In rats, the effects on fertility were reversible 22 weeks after dosing; however, the effects in humans are unknown 
           
 
  <content styleCode="italics">[see Nonclinical Toxicology (
            
  
   <linkHtml href="#ID_7ca764cb-6802-43b0-9ba0-4930fc1aa431">13.1</linkHtml>)]
           
 
  </content>.
          

 </paragraph>
                           </text>
                           <effectiveTime value="20191112"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_56cad7cd-a7f1-4d0c-8291-8b49a6a4ad9a">
                     <id root="f489c20d-da59-e468-e053-2a95a90aa587"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of Benznidazole Tablets have been established in pediatric patients 2 to 12 years of age for the treatment of Chagas disease. Use in pediatric patients 2 to 12 years of age was established in two adequate and well-controlled trials in pediatric patients 6 to 12 years old with additional safety and pharmacokinetic data from pediatric patients 2 to 6 years of age 
  <content styleCode="italics">[see Dosage and Administration ( 
   <linkHtml href="#ID_22b5ac3f-bdb3-4066-a5e8-749a5c8010bf">2.2</linkHtml>), Adverse Reactions ( 
   <linkHtml href="#ID_fec6e961-8cc3-4e30-961c-9f6e4bd7c55a">6.1</linkHtml>), Clinical Studies ( 
   <linkHtml href="#ID_36d25ff4-24ff-4b20-ad94-6b4c7d368f4d">14</linkHtml>)]
  </content>.
 </paragraph>
                        <paragraph>Safety and effectiveness in pediatric patients below the age of 2 years and above the age of 12 years have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20170829"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_cad26f03-d756-4ccb-b179-fee32d6e7ad4">
                     <id root="b8b78936-ecbb-898a-e053-2a95a90a7ca7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Hepatic Impairment </title>
                     <text>
                        <paragraph>Use of Benznidazole Tablets has not been evaluated in patients with hepatic impairment.</paragraph>
                     </text>
                     <effectiveTime value="20170829"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_8ff83eb3-64f6-41a8-9862-41784aa9a1ce">
                     <id root="b8b78936-ecbc-898a-e053-2a95a90a7ca7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7 Renal Impairment </title>
                     <text>
                        <paragraph>Use of Benznidazole Tablets has not been evaluated in patients with renal impairment.</paragraph>
                     </text>
                     <effectiveTime value="20170829"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3f3d3415-6590-43ea-b606-f90aec81dfd2">
               <id root="b8b78936-ecbd-898a-e053-2a95a90a7ca7"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>Benznidazole Tablets contain benznidazole, a nitroimidazole antimicrobial. The chemical name of benznidazole is N-benzyl-2-(2-nitro-1H-imidazol-1-yl) acetamide. The empirical formula is C
       
 
  <sub>12</sub>H
       
 
  <sub>12</sub>N
       
 
  <sub>4</sub>O
       
 
  <sub>3</sub> and the molecular weight is 260.246 g/mol. The structural formula is:
      

 </paragraph>
                  <paragraph styleCode="MultiMediaCaption">
                     <renderMultiMedia referencedObject="Lbc9d2dfb-c436-4492-a3fb-1030a81f8212"/>
                  </paragraph>
                  <paragraph styleCode="MultiMediaCaption">Figure 1: Benznidazole Structure</paragraph>
                  <paragraph>Benznidazole is a yellowish, practically crystalline powder that is practically insoluble in water, sparingly soluble in acetone and ethanol, and slightly soluble in methanol.</paragraph>
                  <paragraph>Benznidazole Tablets are white round tablets each containing 12.5 mg or 100 mg of benznidazole, for oral use. The 100 mg white tablets are round and functionally scored twice as a cross on both sides debossed with “E” on one side of each quarter portion. The 12.5 mg white tablets are round and unscored debossed with “E” on one side.</paragraph>
                  <paragraph>The inactive ingredients are as follows: magnesium stearate, NF; microcrystalline cellulose, NF; monohydrate lactose, NF; pre-gelatinized corn starch, NF; and sodium croscarmellose, NF.</paragraph>
               </text>
               <effectiveTime value="20190531"/>
               <component>
                  <observationMedia ID="Lbc9d2dfb-c436-4492-a3fb-1030a81f8212">
                     <text>structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3e81dd82-1e79-4e50-ae9f-4a7ffcece81c">
               <id root="f489e0d0-0eee-692f-e053-2a95a90ac191"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20211215"/>
               <component>
                  <section ID="ID_c5ee1447-8f0a-402b-95b6-43f1401723e1">
                     <id root="b8b78936-ecbf-898a-e053-2a95a90a7ca7"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Benznidazole is a nitroimidazole antimicrobial drug 
         
 
  <content styleCode="italics">[see Microbiology (
          
  
   <linkHtml href="#ID_6868069c-c017-4190-99df-cb2bb2443d9d">12.4</linkHtml>)]
         
 
  </content>.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20170829"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_82d9bea2-5c0b-4413-aa0d-bb89448219c8">
                     <id root="b8b78936-ecc0-898a-e053-2a95a90a7ca7"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>The pharmacodynamics of benznidazole is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20170829"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_5ad02d1c-1e0a-449e-b0cc-fd677b08afe2">
                     <id root="f489c71c-3674-e7cf-e053-2995a90a5b7a"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption </content>
                        </paragraph>
                        <paragraph>The absorption of benznidazole from three different 100 mg benznidazole preparations was comparable when administered as a single dose under fasting conditions in adult healthy volunteers ( 
  <linkHtml href="#_Ref492920056">Table 6</linkHtml>).
 </paragraph>
                        <table width="100%">
                           <caption>Table 6: Summary of Benznidazole Pharmacokinetic (PK) Parameters Following a Single Oral Dose of 100 mg Benznidazole Administered Under Fasting Conditions in Adult Healthy Volunteers.</caption>
                           <tbody>
                              <tr>
                                 <td/>
                                 <td align="center" colspan="3" styleCode="Botrule">Preparations for 100 mg Benznidazole Oral Dose</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule"/>
                                 <td align="center" styleCode="Botrule">One Benznidazole 100 mg Tablet Taken Whole</td>
                                 <td align="center" styleCode="Botrule">Slurry prepared with one Benznidazole 100 mg Tablet</td>
                                 <td align="center" styleCode="Botrule">Slurry prepared with eight Benznidazole 12.5 mg Tablets</td>
                              </tr>
                              <tr>
                                 <td align="center">Parameter</td>
                                 <td align="center">Mean (SD)</td>
                                 <td align="center">Mean (SD)</td>
                                 <td align="center">Mean (SD)</td>
                              </tr>
                              <tr>
                                 <td align="center">Cmax (mg/L)</td>
                                 <td align="center">2.4 (0.5)</td>
                                 <td align="center">2.4 (0.4)</td>
                                 <td align="center">2.4 (0.4)</td>
                              </tr>
                              <tr>
                                 <td align="center">Tmax a(h)</td>
                                 <td align="center">2 (1-4)</td>
                                 <td align="center">2 (0.5-4)</td>
                                 <td align="center">2 (1 - 4.5)</td>
                              </tr>
                              <tr>
                                 <td align="center">AUC (mg*h/L)</td>
                                 <td align="center">43.5 (9.0)</td>
                                 <td align="center">41.8 (9.6)</td>
                                 <td align="center">44.1 (11.8)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a</sup> Tmax is presented as median (range)
 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Effect of Food</content>
                        </paragraph>
                        <paragraph>Benznidazole Cmax and AUC were not affected by the administration of Benznidazole 100 mg tablet with a high-fat, high-caloric meal (approximately 1034 total kcal, 67 kcal from fat, 42 kcal from carbohydrates, 59 kcal from protein) compared with fasted conditions in adult healthy volunteers. Serum concentrations of benznidazole reached peak levels at 3.2 hours (1-10 hours) after administration of Benznidazole Tablets 100 mg tablet after a high-fat, high-caloric meal, and at 2.0 hours (0.5-4 hours) in fasted conditions 
  <content styleCode="italics">[see Dosage and Administration ( 
   <linkHtml href="#ID_befd77e5-2f47-4dcf-bb3a-76c131c2edba">2.1</linkHtml>)] 
  </content>.
 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Protein binding is reported to be approximately 44 to 60 %. The mean blood:plasma radioactivity ratios, ranging from 0.63 to 1.10, suggest that there is no preferential distribution of benznidazole into the red blood cells. The apparent volume of distribution of benznidazole is approximately 45 L.</paragraph>
                        <paragraph>
                           <br/>
                           <br/>
                           <content styleCode="underline">Elimination</content>
                           <br/>
                           <br/>
The elimination half-life of benznidazole is approximately 13 hours in healthy volunteers following single dose. The apparent total clearance of benznidazole is about 2.3 L/h.
 </paragraph>
                        <paragraph>
                           <br/>
                           <br/>
                           <content styleCode="italics">Metabolism</content>
                           <br/>
                           <br/>
In plasma, benznidazole parent drug is the most abundant component, accounting for approximately 80% of the total drug related exposure and no major circulating metabolites were identified. The primary benznidazole metabolism pathway is indicated to be nitro reduction followed by glucuronidation.
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Following oral administration of 100 mg radiolabeled benznidazole, about 68% and 21% of the radioactivity is recovered in urine (6% of total dose as unchanged parent drug) and feces (unchanged parent drug not detected), respectively.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>The effect of sex, race, renal impairment, or hepatic impairment on the pharmacokinetics of benznidazole is unknown.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>In vitro studies showed that benznidazole is a P-gp substrate and does not notably induce Cytochrome P450 enzymes 1A2, 2B6, and 3A4 at concentrations up to 100 mcM.</paragraph>
                     </text>
                     <effectiveTime value="20191113"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_6868069c-c017-4190-99df-cb2bb2443d9d">
                     <id root="b8b78936-ecc2-898a-e053-2a95a90a7ca7"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Mechanism of Action</content>
                        </paragraph>
                        <paragraph>Benznidazole inhibits the synthesis of DNA, RNA, and proteins within the 
         
 
  <content styleCode="italics">T. cruzi</content> parasite. Studies suggest that benznidazole is reduced by a Type I nitroreductase (NTR) enzyme of 
         
 
  <content styleCode="italics">T. cruzi</content> producing a series of short-lived intermediates that may promote damage to several macromolecules including DNA. In mammalian cells, however, benznidazole is metabolized by reduction of the nitro group to an amino group by a Type II NTR enzyme. The precise mechanism of action is not known.  
        

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Antimicrobial Activity</content>
                        </paragraph>
                        <paragraph>Benznidazole is active against all three stages, trypomastigotes, amastigotes, and epimastigotes, of 
         
 
  <content styleCode="italics">T. cruzi</content>.  However, the sensitivity of 
         
 
  <content styleCode="italics">T. cruzi</content> strains to benznidazole, from different geographic regions, may vary.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Resistance </content>
                        </paragraph>
                        <paragraph>Studies 
         
 
  <content styleCode="italics">in vitro</content> and in mice infected with 
         
 
  <content styleCode="italics">T. cruzi</content> suggest a potential for development of resistance to benznidazole.  
        

 </paragraph>
                        <paragraph>The mechanisms of drug resistance appear to be multifactorial. These mechanisms include decreased activity due to a mutation in the nitroreductase (
         
 
  <content styleCode="italics">TcNTR</content>) gene. Other mechanisms include higher efflux activity due to over expression of 
         
 
  <content styleCode="italics">TcPGP
          
  
   <sub>1</sub>
                           </content> and 
         
 
  <content styleCode="italics">TcPGP
          
  
   <sub>2</sub>
                           </content> genes that encode p-glycoprotein as well as 
         
 
  <content styleCode="italics">TcABCG1</content> genes that encode ATP-binding cassette transporters. Also, some studies reported overexpression of other genes 
         
 
  <content styleCode="italics">TcFeSOD-A</content> and 
         
 
  <content styleCode="italics">TcCyP19</content> that encode superoxide dismutase and cyclophilin, respectively, which have diverse biological function and may help parasite survival. However, the clinical relevance of these findings is not known.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20170829"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_761ed2d3-bd62-4368-999d-a23f11954031">
               <id root="f489e0d0-0eed-692f-e053-2a95a90ac191"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20211215"/>
               <component>
                  <section ID="ID_7ca764cb-6802-43b0-9ba0-4930fc1aa431">
                     <id root="f489ce39-49a6-2a9c-e053-2a95a90a8886"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenicity</content>
                        </paragraph>
                        <paragraph>Long-term carcinogenicity studies for benznidazole have not been performed.</paragraph>
                        <paragraph>Nitroimidazoles, which have similar chemical structures to benznidazole have been reported to be carcinogenic in mice and rats.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Genetic Toxicity</content>
                        </paragraph>
                        <paragraph>Genotoxicity of benznidazole has been demonstrated in vitro in several bacterial species and mammalian cell systems and in vivo in mammals.</paragraph>
                        <paragraph>Benznidazole was mutagenic in several strains of 
  <content styleCode="italics">S. typhimurium</content> (TA 100, 102 1535, 1537, 1538, 97, 98 99 53 and UTH8414), 
  <content styleCode="italics">E.coli</content>, and 
  <content styleCode="italics">K. pneumoniae</content>.
 </paragraph>
                        <paragraph>Benznidazole was genotoxic in several in vitro mammalian cell assays including a chromosome aberration assay in human lymphocytes and in sister chromatid exchange assays in human lymphocytes and in Human Hep G2 cells.</paragraph>
                        <paragraph>In vivo, benznidazole was shown to be positive for genotoxicity in a mouse bone marrow micronucleus assay, in mouse and human red blood cell micronucleus assays, in a mouse abnormal sperm head assay and in a human peripheral blood lymphocyte assay. However in other micronucleus studies in mice and rats, oral doses of benznidazole did not cause a significant increase in the frequency of chromosomal aberrations in bone marrow cells or micronuclei in peripheral blood cells.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>In a 6-month, chronic repeated-dosing study with Wistar rats, benznidazole was shown to produce dose-dependent testicular and epididymal atrophy at a dose of 30 mg/kg/day (approximately equivalent to 0.6 times the MRHD based on whole body surface area comparisons). Aspermia was also evident in affected rats, but fertility was not assessed in this study. The benznidazole dose that was not associated with adverse effects in this study was considered to be 10 mg/kg/day (5 mg/kg twice daily) in males which is approximately 0.2-times the MRHD based on whole body surface area comparison. In other literature reports, benznidazole has been shown to cause testicular atrophy and inhibit spermatogenesis in pubertal and adult rats and mice 
  <sup>5-7</sup>.
 </paragraph>
                        <paragraph>In a male fertility study, benznidazole was administered by oral (gavage) administration in daily doses of 10, 30, and 100 mg/kg/day to male Wistar rats beginning 10 weeks before mating, through mating, and for two weeks after mating for a total of 14-weeks. At the end of the dosing period, testicular and epididymal weights and the percent of normal sperm were decreased in mid- and high-dose males compared to control values. Also altered gonadal function, mating behavior and reduced fertility associated with morphologically and functionally altered sperm and histological changes in the testes and epididymides was observed in high-dose males. However, after a 22-week treatment-free period, almost complete recovery was observed with fully restored fertility compared to control values. After the 22-week treatment-free period the remaining benznidazole-related effects included reduced testicular and epididymal weights (10-22% reduction in absolute weight) compared to control values at the high benznidazole dose of 100 mg/kg/day (equivalent to approximately 2 times the MRHD based on whole body surface area comparison). The benznidazole dose at which no adverse effect was observed was 10 mg/kg/day which is equivalent to approximately 0.2 times the MRHD based on whole body surface area comparison.</paragraph>
                        <paragraph>
                           <br/>
                           <br/>
In a female fertility study, benznidazole was administered by oral gavage to female Wistar rats in doses of 15, 50, and 150 mg/kg/day for a 2-week pre-mating period, during mating, and through day 7 of gestation. The high dose was associated with transient lower body weight gain and food consumption. There were no benznidazole-related effects on mating performance or fertility and no adverse macroscopic or reproductive organ weight changes. However, higher post-implantation loss with lower live litter size was observed at the high dose of 150 mg/kg/day (equivalent to approximately 3 times the MRHD based on whole body surface area comparison). The benznidazole dose that was not associated with adverse effects for this study was considered to be 50 mg/kg/day which is approximately equivalent to the MRHD based on whole body surface area comparison.
 </paragraph>
                     </text>
                     <effectiveTime value="20191112"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1a15b9eb-5c29-4f58-978b-7f8b0a44dee9">
                     <id root="f489c71c-3675-e7cf-e053-2995a90a5b7a"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>Single oral dose toxicity studies in rats have established that benznidazole causes ultrastructural changes in the adrenal cortex, colon, esophagus, ovaries, and testis 
  <sup>5, 8-11</sup>. In these tissues, these changes were associated with the presences of nitro reductase activity, the production of reactive metabolites, and/or covalent binding of metabolites.
 </paragraph>
                        <paragraph>Neurotoxicity including brain axonal degeneration and Purkinje cell degeneration was observed with repeated-oral dosing in dogs without adverse changes in peripheral nerves 
  <sup>12-14</sup>. Neurological signs included: apathy, hypertonia, hyperreflexia, ataxia, loss of balance, oscillatory movements of the trunk and head, strong contractions of the back and leg muscles, opisthotonos and nystagmus. Neurotoxicity was not observed in other test species, including mouse, rat, guinea pig, and rabbit.
 </paragraph>
                     </text>
                     <effectiveTime value="20191113"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_36d25ff4-24ff-4b20-ad94-6b4c7d368f4d">
               <id root="b8b78936-ecc6-898a-e053-2a95a90a7ca7"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <text>
                  <paragraph>The safety and effectiveness of benznidazole for the treatment of Chagas disease in patients 6 to 12 years of age was established in two adequate and well-controlled trials (Trial 1 and Trial 2) as described below.</paragraph>
                  <paragraph>Trial 1 was a randomized, double-blind, placebo-controlled trial in children 6 to 12 years of age with chronic indeterminate Chagas disease conducted in Argentina. The chronic indeterminate form of Chagas disease includes patients with serologic evidence of 
       
 
  <content styleCode="italics">T. cruzi</content> infection without symptoms of cardiac or gastrointestinal disease. A total of 106 patients were randomized to receive either benznidazole (5 mg/kg/day for 60 days) or placebo and followed for 4 years. Patients with at least two positive conventional serologic tests for antibodies to 
       
 
  <content styleCode="italics">T. cruzi</content> were included in the study. The conventional serologic tests used include indirect hemagglutination assay (IHA), immunofluorescence antibody assay (IFA), and/or enzyme linked immunosorbent assay (ELISA) and were based on the detection of antibodies against 
       
 
  <content styleCode="italics">T. cruzi</content> parasites.
      

 </paragraph>
                  <paragraph>Trial 2 was a randomized, double-blind, placebo-controlled trial in pediatric patients 7 to 12 years of age with chronic indeterminate Chagas disease conducted in Brazil. A total of 129 patients were randomized to receive either benznidazole (7.5 mg/kg/day for 60 days) or placebo and followed for 3 years. Patients with three positive conventional serologic tests for antibodies to 
       
 
  <content styleCode="italics">T. cruzi</content> were included in the study. The conventional serologic tests include IHA, IFA, and/or ELISA and were based on the detection of antibodies against 
       
 
  <content styleCode="italics">T. cruzi</content> parasites.
      

 </paragraph>
                  <paragraph>Both trials measured antibodies by conventional and nonconventional assays. The nonconventional assays include F29-ELISA and AT- chemiluminescence-ELISA that are based on detection of anti-
       
 
  <content styleCode="italics">T. cruzi</content> IgG antibodies against the recombinant antigens, F29 and AT from the flagella of 
       
 
  <content styleCode="italics">T. cruzi</content> parasites. Benznidazole treatment resulted in a significantly higher percentage of seronegative patients by a nonconventional assay. Results at the end of follow-up are reported in the following table.
      

 </paragraph>
                  <table ID="_RefID0EDBBG" width="100%" cellpadding="3.6pt">
                     <caption>Table 7: Nonconventional ELISA
        
  
   <sup>a</sup> Serologic Status at End-of-Follow-Up (mITT population
        
  
   <sup>b</sup>)
       
 
  </caption>
                     <col width="27%"/>
                     <col width="23%"/>
                     <col width="22%"/>
                     <col width="28%"/>
                     <tfoot>
                        <tr styleCode="First Last">
                           <td colspan="4" align="left" styleCode="Botrule" valign="top">
                              <sup>a</sup> Enzyme-linked immunosorbent assay (F29 ELISA in Study Trial 1 and AT chemiluminescence-ELISA in Trial 2); the F29 and AT antigens represent antigens from the flagella of 
          
    
     <content styleCode="italics">T. cruzi</content> parasites.
          
    
     <br/>
                              <sup>b</sup> Modified intent to treat (mITT) population includes subjects who are positive for the assay at baseline;
          
    
     <br/>
                              <sup>c</sup> Exact confidence intervals presented.
         
   
    </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Toprule" valign="middle"/>
                           <td align="center" styleCode="Botrule Toprule" valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Benznidazole</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Toprule" valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Placebo</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Toprule" valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Difference (95% CI)</content>
                                 <sup>c</sup>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Trial 1</content>
                              </paragraph>
                           </td>
                           <td align="center" valign="middle">
                              <paragraph>N=40</paragraph>
                           </td>
                           <td align="center" valign="middle">
                              <paragraph>N=37</paragraph>
                           </td>
                           <td valign="middle"/>
                        </tr>
                        <tr>
                           <td align="center" valign="middle">
                              <paragraph>Seronegative</paragraph>
                           </td>
                           <td align="center" valign="middle">
                              <paragraph>24 (60.0)</paragraph>
                           </td>
                           <td align="center" valign="middle">
                              <paragraph>5 (13.5)</paragraph>
                           </td>
                           <td align="center" valign="middle">
                              <paragraph>46.5 (24.5, 64.4)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="middle">
                              <paragraph>Seropositive</paragraph>
                           </td>
                           <td align="center" valign="middle">
                              <paragraph>15</paragraph>
                           </td>
                           <td align="center" valign="middle">
                              <paragraph>29</paragraph>
                           </td>
                           <td valign="middle"/>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule" valign="middle">
                              <paragraph>Missing</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule" valign="middle">
                              <paragraph>1</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule" valign="middle">
                              <paragraph>3</paragraph>
                           </td>
                           <td styleCode="Botrule" valign="middle"/>
                        </tr>
                        <tr>
                           <td align="center" valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Trial 2</content>
                              </paragraph>
                           </td>
                           <td align="center" valign="middle">
                              <paragraph>N=64</paragraph>
                           </td>
                           <td align="center" valign="middle">
                              <paragraph>N=65</paragraph>
                           </td>
                           <td valign="middle"/>
                        </tr>
                        <tr>
                           <td align="center" valign="middle">
                              <paragraph>Seronegative</paragraph>
                           </td>
                           <td align="center" valign="middle">
                              <paragraph>35 (54.7)</paragraph>
                           </td>
                           <td align="center" valign="middle">
                              <paragraph>3 (4.6)</paragraph>
                           </td>
                           <td align="center" valign="middle">
                              <paragraph>50.1 (35.8, 63.4)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="middle">
                              <paragraph>Seropositive</paragraph>
                           </td>
                           <td align="center" valign="middle">
                              <paragraph>23</paragraph>
                           </td>
                           <td align="center" valign="middle">
                              <paragraph>51</paragraph>
                           </td>
                           <td valign="middle"/>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule" valign="middle">
                              <paragraph>Missing</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule" valign="middle">
                              <paragraph>6</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule" valign="middle">
                              <paragraph>11</paragraph>
                           </td>
                           <td styleCode="Botrule" valign="middle"/>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>In Trial 1 using conventional ELISA, 4 of 53 (7.5%) benznidazole subjects and 2 of 50 (4.0%) placebo subjects seroconverted to negative by the end of follow-up (difference 3.5, 95% CI (-7.0, 14.9)). In Trial 2 using conventional ELISA, 4 of 64 (6.3%) of benznidazole subjects and 0 of 65 placebo subjects seroconverted to negative by the end of follow-up (difference 6.3, 95% CI (0.3, 15.2)).</paragraph>
               </text>
               <effectiveTime value="20191112"/>
            </section>
         </component>
         <component>
            <section ID="ID_4738055c-3c83-40bd-a6fd-6135de188ab8">
               <id root="b8b78936-ecc7-898a-e053-2a95a90a7ca7"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES </title>
               <text>
                  <list listType="ordered">
                     <item>Sosa Estani S, et al., 1998, Efficacy of Chemotherapy with Benznidazole in Children in the Indeterminate Phase of Chagas' Disease. Am J Trop Med Hyg 59: 526-529.
       </item>
                     <item>de Andrade, Ana Lucia S. Sgambatti, et al., 1996, Randomised Trial of Efficacy of Benznidazole in Treatment of Early 
        
  
   <content styleCode="italics">Trypanosoma cruzi</content> Infection. Lancet 348: 1407-1413.
       
 
  </item>
                     <item>Altcheh, Jaime, et al., 2014, Population Pharmacokinetic Study of Benznidazole in Pediatric Chagas Disease Suggests Efficacy Despite Lower Plasma Concentrations than in Adults. PLoS Negl Trop Dis 8:e2907.
       </item>
                     <item>García-Bournissen, F, S Moroni, ME Marson, et al., 2015, Limited Infant Exposure to Benznidazole Through Breast Milk During Maternal Treatment for Chagas Disease. Arch Dis Child 100:90-94.
       </item>
                     <item>Bernacchi, AS, CR de Castro, EG de Toranzo, and JA Castro, 1986, Effects of Nifurtimox or Benznidazole Administration on Rat Testes: Ultrastructural Observations and Biochemical Studies, Exp Mol Pathol 45: 245-256.
       </item>
                     <item>Vieira, CL, TL Lamano-Carvalho, AL Favaretto, MM Valenca, J Antunes-Rodridgues, and AA Barreira, 1989, Testes Alterations in Pubertal Benznidazole-treated Rats, Braz J Med Biol Res, 22: 695-698.
       </item>
                     <item>Navarro, ML and R Nagel, 1990, Abnormal Sperm Induced in Mice by Oral Administration of Antichagasic Drugs, Comunicaciones Biologicas, 8: 251-258.
       </item>
                     <item>de Castro, RC, EG Diaz de Toranzo, and JA Castro, 1992, Benznidazole-induced Ultrastructural Alterations in Rat Adrenal Cortex: Mechanistic Studies, Toxicology, 74: 223-232.
       </item>
                     <item>Diaz, EG, RC de Castro, M Montalto de Mecca, and JA Castro, 2000, Benznidazole-induced Ultrastructural and Biochemical Alterations in Rat Colon, Acta Pharmacol Sin, 21: 961-966.
       </item>
                     <item>de Castro, RC, M Montalto de Mecca, SL Fanelli, EC de Ferreyra, EG Diaz, and JA Castro, 2003, Benznidazole-induced Ultrastructural and Biochemical Alterations in Rat Esophagus, Toxicology, 191: 189-198.
       </item>
                     <item>de Castro, CR, EGD de Toranzo, AS Bernacchi, M Carbone, and JA Castro, 1989, Ultrastructural Alterations in Ovaries from Nifurtimox or Benznidazole-treated Rats: Their Relation to Ovarian Nitroreductive Biotransformation of Both Drugs, Exp Mol Pathol, 50: 385-397.
       </item>
                     <item>Scharer, K, 1972, Selective Purkinje Cell Damage in Dogs after Oral Administration of High Doses of Nitroimidazole Derivatives, Verhandlungen der Deutschen Gesellschaft fur Pathologie, 56: 407-10.
       </item>
                     <item>Flores-Vieira, CLL and AA Barreira, 1997a,  Experimental Benznidazole Encephalopathy: I. Clinical-Neurological Alterations, J Neurol Sci, 150: 3-11.
       </item>
                     <item>Flores-Vieira, CLL, L Chimelli, RMF Fernandez, and AA Barreira, 1997b, Experimental Benznidazole Encephalopathy: II. Electroencephalographic and Morphological Alterations, J Neurol Sci, 150:13-25.
       </item>
                  </list>
               </text>
               <effectiveTime value="20170829"/>
            </section>
         </component>
         <component>
            <section ID="ID_845616a1-0a69-4dac-88cb-fc4654fd9f1e">
               <id root="b8b78936-ecc8-898a-e053-2a95a90a7ca7"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <effectiveTime value="20170829"/>
               <component>
                  <section ID="ID_93e2880c-e6ae-44f8-a0a5-23948b2c03a6">
                     <id root="b8b78936-ecc9-898a-e053-2a95a90a7ca7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.1 How Supplied </title>
                     <text>
                        <paragraph>Benznidazole Tablets (12.5 mg or 100 mg) are supplied as follows:</paragraph>
                        <list listType="unordered">
                           <item>100 mg white tablets, round and functionally scored twice as a cross on both sides.  Each tablet is about 10 mm in diameter debossed with “E” on one side of each quarter portion.
         </item>
                           <item>12.5 mg white tablets, round and unscored.  Each tablet is about 5 mm in diameter debossed with “E” on one side.
         </item>
                        </list>
                        <paragraph>Benznidazole Tablets 100 mg are available in bottles of 100 tablets (NDC 0642-7464-10).</paragraph>
                        <paragraph>Benznidazole Tablets 12.5 mg are available in bottles of 100 tablets (NDC 0642-7463-12).</paragraph>
                     </text>
                     <effectiveTime value="20170829"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_55ea574d-83cf-43bd-a146-9154d67194fa">
                     <id root="b8b78936-ecca-898a-e053-2a95a90a7ca7"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.2 Storage and Handling </title>
                     <text>
                        <paragraph>Store at controlled room temperature 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].  Keep bottle tightly closed and protect from moisture.</paragraph>
                     </text>
                     <effectiveTime value="20170829"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_c857d369-1e8b-4c09-b2f0-0eb89a8d9d51">
               <id root="b8b78936-eccb-898a-e053-2a95a90a7ca7"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (
       
 
  <linkHtml href="#ID_f8c9510f-0e3c-4546-bb1c-bb53d9adcf5b">Instructions for Use</linkHtml>).
      

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Embryo-Fetal Toxicity</content>
                  </paragraph>
                  <paragraph>Advise pregnant women and females of reproductive potential that exposure to Benznidazole Tablets during pregnancy can result in fetal harm.</paragraph>
                  <paragraph>Advise females to inform their healthcare provider of a known or suspected pregnancy 
       
 
  <content styleCode="italics">[see Warnings and Precautions (
        
  
   <linkHtml href="#ID_8e159c11-bef9-4e18-8869-8636261b77c0">5.2</linkHtml>) and Use in Specific Populations (
        
  
   <linkHtml href="#ID_e5a4b606-4d6b-4c5b-b890-622e152979b6">8.1</linkHtml>)]
       
 
  </content>.
      

 </paragraph>
                  <paragraph>Advise females of reproductive potential to use effective contraception while taking</paragraph>
                  <paragraph>Benznidazole Tablets and for 5 days after the last dose 
       
 
  <content styleCode="italics">[see Use in Specific Populations (
        
  
   <linkHtml href="#ID_19558b53-da39-4881-b2c7-ed61bec4dc41">8.3</linkHtml>)]
       
 
  </content>.
      

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise women not to breastfeed during treatment with Benznidazole Tablets 
       
 
  <content styleCode="italics">[see Use in Specific Populations (
        
  
   <linkHtml href="#ID_5f6aae0e-5346-4c53-ba9d-906fce645706">8.2</linkHtml>)]
       
 
  </content>.
      

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Infertility</content>
                  </paragraph>
                  <paragraph>Advise males of reproductive potential that Benznidazole Tablets may impair fertility
       
 
  <content styleCode="italics"> [see Use in Specific Populations (
        
  
   <linkHtml href="#ID_19558b53-da39-4881-b2c7-ed61bec4dc41">8.3</linkHtml>) and Nonclinical Toxicology (
        
  
   <linkHtml href="#ID_7ca764cb-6802-43b0-9ba0-4930fc1aa431">13.1</linkHtml>)]
       
 
  </content>.
      

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Important Administration Instructions</content>
                  </paragraph>
                  <paragraph>Advise patients and parents/caregivers of pediatric patients taking Benznidazole Tablets that:</paragraph>
                  <paragraph>•Benznidazole Tablets 100 mg are functionally scored tablets which can be split into one-half (50 mg) or one-quarter (25 mg) at the scored lines to provide doses less than 100 mg.</paragraph>
                  <paragraph>•Benznidazole Tablets 12.5 mg and 100 mg (whole or split) can be made into a slurry in a specified volume of water for the pediatric population 
       
 
  <content styleCode="italics">[see Dosage and Administration (
        
  
   <linkHtml href="#ID_2280bef5-a99d-4273-a158-cbe2e329feea">2.3</linkHtml>)]
       
 
  </content>.
      

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypersensitivity Skin Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients that serious skin reactions can occur with Benznidazole Tablets. In case of skin reactions, presenting with additional symptoms of systemic involvement such as lymphadenopathy, fever and/or purpura, discontinuation of treatment is necessary.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Central and Peripheral Nervous System Effects</content>
                  </paragraph>
                  <paragraph>Advise patients that treatment can potentially cause paresthesia or symptoms of peripheral neuropathy. In cases where neurological symptoms occur, immediate discontinuation of treatment is recommended.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hematological Manifestations of Bone Marrow Depression</content>
                  </paragraph>
                  <paragraph>Advise patients that there have been hematological manifestations of bone marrow depression, such as anemia and leukopenia, which are reversible, and normalized after treatment discontinuation.</paragraph>
                  <paragraph/>
                  <paragraph>Manufactured for Chemo Research, S.L.
       
 
  <br/>Madrid, Spain
      

 </paragraph>
                  <paragraph>Manufactured by Laboratorios Liconsa S.A.
       
 
  <br/>Guadalajara, Spain
      

 </paragraph>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lce1f21ee-e902-460a-a9ff-7d1d5e414dd6"/>
                  </paragraph>
                  <paragraph>Exeltis USA, Inc. 
       
 
  <br/>Florham Park, NJ 07932
      

 </paragraph>
               </text>
               <effectiveTime value="20191113"/>
               <component>
                  <observationMedia ID="Lce1f21ee-e902-460a-a9ff-7d1d5e414dd6">
                     <text>exeltis</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f8c9510f-0e3c-4546-bb1c-bb53d9adcf5b">
               <id root="b8b78936-eccc-898a-e053-2a95a90a7ca7"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>INSTRUCTIONS FOR USE </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">BENZNIDAZOLE</content>
                     <br/>
                     <content styleCode="bold">tablets, for oral use</content>
                  </paragraph>
                  <paragraph>Read this Instructions for Use before you start taking BENZNIDAZOLE and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or treatment.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">Note:</content>
                     </content>
                  </paragraph>
                  <paragraph>• Your doctor may need to change your dose of BENZNIDAZOLE during treatment as needed.</paragraph>
                  <paragraph>• BENZNIDAZOLE 100 mg tablets can be taken whole or broken at scored lines.</paragraph>
                  <paragraph>• BENZNIDAZOLE 100 mg tablets are marked with scored lines and may be broken at these scored lines to provide the following doses: 75 mg, 50 mg and 25 mg.</paragraph>
                  <paragraph>
                     <content styleCode="bold">100 mg treatment (take the whole tablet)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="Ld34c2885-f78d-47f8-9d5a-6f9cd6a4a685"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">How to break your BENZNIDAZOLE 100 mg tablet:</content>
                  </paragraph>
                  <paragraph>• Hold the tablet between your thumbs and index fingers close to the scored line (
       
 
  <content styleCode="bold">See Figure 1</content>).
      

 </paragraph>
                  <paragraph>• Apply enough pressure to break the tablet at the scored line (
       
 
  <content styleCode="bold">See Figure 2</content>).
      

 </paragraph>
                  <paragraph>• Only use a tablet that has been broken at the scored line (
       
 
  <content styleCode="bold">See Figure 3</content>).
      

 </paragraph>
                  <paragraph>•
       
 
  <content styleCode="bold">Do not </content>break the BENZNIDAZOLE 100 mg tablet in any other way.
      

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L3cdd6147-4c35-4ebc-a2a9-93e1b7911936"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">75 mg treatment </content>(take one-half of the tablet and one-fourth of the tablet)
      

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L153c3883-593e-4600-9643-16069c501449"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">50 mg treatment </content>(take one-half of the tablet)
      

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L422a36a5-a59f-4fa4-b561-7080d57d6c76"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">25 mg treatment </content>(take one-fourth of the tablet)
      

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L512dd9a9-f37e-46b1-a4d2-e43384f93968"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I store BENZNIDAZOLE?</content>
                  </paragraph>
                  <paragraph>• Store BENZNIDAZOLE at room temperature 20° to 25°C (68°to 77°F).</paragraph>
                  <paragraph>• Keep BENZNIDAZOLE in the bottle that it comes in and keep the bottle tightly closed.</paragraph>
                  <paragraph>• Keep BENZNIDAZOLE away from moisture.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep BENZNIDAZOLE and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>Manufactured by: Laboratori
       
 
  <content styleCode="underline">o</content>s Liconsa S.A., Guadalajara, Spain
      

 </paragraph>
                  <paragraph>Issued: August 2017</paragraph>
               </text>
               <effectiveTime value="20190531"/>
               <component>
                  <observationMedia ID="Ld34c2885-f78d-47f8-9d5a-6f9cd6a4a685">
                     <text>100-mg-treatment</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L3cdd6147-4c35-4ebc-a2a9-93e1b7911936">
                     <text>break-tablet</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L153c3883-593e-4600-9643-16069c501449">
                     <text>75-mg-treatment</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L422a36a5-a59f-4fa4-b561-7080d57d6c76">
                     <text>50-mg-treatment</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L512dd9a9-f37e-46b1-a4d2-e43384f93968">
                     <text>25-mg-treatment</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_b6ae2dfa-7adb-4601-8673-439abb098b84">
               <id root="2f9e1b06-f6b9-7255-e063-6394a90a5422"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 100 mg CARTON</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_2f9dc933-b66b-5583-e063-6394a90a599b"/>
                  </paragraph>
                  <paragraph>NDC 0642-7464-10</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Benznidazole tablets
  <br/>
                     <content styleCode="bold">100 mg</content>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>For oral use
  <br/>
Rx only
  <br/>
100 tablets
 </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Exeltis</content>
                     <br/>
Rethinking healthcare
 </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Keep out of the reach of children.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Store at controlled room temperature
  <br/>
20° to 25°C (68° to 77°F)
  <br/>
Keep bottle tightly closed and protect
 </paragraph>
                  <paragraph>from moisture.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Manufactured for Chemo Research, S.L.,
  <br/>
Madrid, Spain.
 </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Manufactured by Laboratorios Liconsa S.A.,
  <br/>
Avenida Miralcampo 7,
  <br/>
Pol. Ind. Miralcampo, Azuqueca de Henares,
  <br/>
Guadalajara 19200, Spain.
 </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Distributed by Exeltis USA, Inc.,
  <br/>
Florham Park, NJ, USA.
 </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>1-877-324-9349 www.exeltisusa.com
  <br/>
©2019 All Rights Reserved. Exeltis USA, Inc.
 </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>See prescribing information
  <br/>
for Dosage and
  <br/>
Administration.
 </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Benznidazole
  <br/>
tablets
  <br/>
100 mg
 </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Benznidazole tablets
  <br/>
                     <content styleCode="bold">100 mg</content>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Lot No.:
  <br/>
                     <br/>
Expiry date:
 </paragraph>
               </text>
               <effectiveTime value="20190531"/>
               <component>
                  <observationMedia ID="img_2f9dc933-b66b-5583-e063-6394a90a599b">
                     <text>carton-100-mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_499d364c-ef0b-4a38-906f-1e2069c1eca6">
               <id root="2f9e0ded-e3c9-717d-e063-6394a90a79c1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 12.5 mg CARTON</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_2f9dc983-0d9d-f011-e063-6294a90a816d"/>
                  </paragraph>
                  <paragraph>NDC 0642-7463-12</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Benznidazole tablets
  <br/>
                     <content styleCode="bold">12.5 mg</content>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>For oral use
  <br/>
Rx only
  <br/>
100 tablets
 </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Exeltis</content>
                     <br/>
Rethinking healthcare
 </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Keep out of the reach of children.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Store at controlled room temperature
  <br/>
20° to 25°C (68° to 77°F)
  <br/>
Keep bottle tightly closed and protect
  <br/>
from moisture.
 </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Manufactured for Chemo Research, S.L.,
  <br/>
Madrid, Spain.
 </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Manufactured by Laboratorios Liconsa S.A.,
  <br/>
Avenida Miralcampo 7,
  <br/>
Pol. Ind. Miralcampo, Azuqueca de Henares,
  <br/>
Guadalajara 19200, Spain.
 </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Distributed by Exeltis USA, Inc.,
  <br/>
Florham Park, NJ, USA.
 </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>1-877-324-9349 www.exeltisusa.com
  <br/>
©2019 All Rights Reserved. Exeltis USA, Inc.
 </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>See prescribing information
  <br/>
for Dosage and
  <br/>
Administration.
 </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Benznidazole
  <br/>
tablets
  <br/>
12.5 mg
 </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Benznidazole tablets
  <br/>
                     <content styleCode="bold">12.5 mg</content>
                  </paragraph>
                  <paragraph/>
                  <paragraph>Lot No.:
  <br/>
                     <br/>
Expiry date:
 </paragraph>
               </text>
               <effectiveTime value="20190531"/>
               <component>
                  <observationMedia ID="img_2f9dc983-0d9d-f011-e063-6294a90a816d">
                     <text>carton-12-5-mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>